AIMS: To assess the effects of the protease inhibitor ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers. METHODS: This was an open-label, single centre study in 23 subjects who received two single doses of oral contraceptive containing 50 microg ethinyl oestradiol on Day 1 (alone) and on Day 29 during concomitant ritonavir. Each subject received 16 days of every 12 h doses of ritonavir from Day 15 through Day 30. Blood samples were collected for serum ethinyl oestradiol concentrations for 48 h after each dose and for plasma ritonavir on Day 29 at 0 and 4 h postdose. RESULTS: Statistically significant decreases in ethinyl oestradiol mean Cmax (-32%) and mean AUC (-41%), and a statistically significant increase in the mean terminal elimination rate constant (+31%) were observed during concomitant ritonavir. The harmonic mean terminal half-life decreased from 17 h to 13 h during concomitant ritonavir. No statistically significant change was noted in tmax. The ratios of means (95% confidence intervals) for Cmax and AUC were 0.682 (0.612-0.758) and 0.595 (0.506-0.694), respectively. The changes in ethinyl oestradiol pharmacokinetics were consistent with an increase in clearance from enzymatic induction of glucuronidation and/or cytochrome P450 hydroxylation. Mean steady-state ritonavir concentrations of 6.5 and 13.4 microg ml(-1) were observed at 0 and 4 h postdose, respectively. CONCLUSIONS: Considering the extent of the decrease in ethinyl oestradiol concentrations, the use of alternate contraceptive measures should be considered when ritonavir is being administered.
AIMS: To assess the effects of the protease inhibitor ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers. METHODS: This was an open-label, single centre study in 23 subjects who received two single doses of oral contraceptive containing 50 microg ethinyl oestradiol on Day 1 (alone) and on Day 29 during concomitant ritonavir. Each subject received 16 days of every 12 h doses of ritonavir from Day 15 through Day 30. Blood samples were collected for serum ethinyl oestradiol concentrations for 48 h after each dose and for plasma ritonavir on Day 29 at 0 and 4 h postdose. RESULTS: Statistically significant decreases in ethinyl oestradiol mean Cmax (-32%) and mean AUC (-41%), and a statistically significant increase in the mean terminal elimination rate constant (+31%) were observed during concomitant ritonavir. The harmonic mean terminal half-life decreased from 17 h to 13 h during concomitant ritonavir. No statistically significant change was noted in tmax. The ratios of means (95% confidence intervals) for Cmax and AUC were 0.682 (0.612-0.758) and 0.595 (0.506-0.694), respectively. The changes in ethinyl oestradiol pharmacokinetics were consistent with an increase in clearance from enzymatic induction of glucuronidation and/or cytochrome P450 hydroxylation. Mean steady-state ritonavir concentrations of 6.5 and 13.4 microg ml(-1) were observed at 0 and 4 h postdose, respectively. CONCLUSIONS: Considering the extent of the decrease in ethinyl oestradiol concentrations, the use of alternate contraceptive measures should be considered when ritonavir is being administered.
Entities:
Keywords:
Acquired Immunodeficiency Syndrome--prevention and control; Americas; Clinical Research; Contraception; Contraceptive Agents, Estrogen--pharmacodynamics; Contraceptive Agents, Female--pharmacodynamics; Contraceptive Agents--pharmacodynamics; Contraceptive Methods; Developed Countries; Diseases; Drug Interactions; Drugs; Ethinyl Estradiol--pharmacodynamics; Family Planning; Hiv Infections--prevention and control; North America; Northern America; Oral Contraceptives; Oral Contraceptives, Combined; Research Methodology; Research Report; Treatment; United States; Viral Diseases
Authors: A Hsu; G R Granneman; G Witt; C Locke; J Denissen; A Molla; J Valdes; J Smith; K Erdman; N Lyons; P Niu; J P Decourt; J B Fourtillan; J Girault; J M Leonard Journal: Antimicrob Agents Chemother Date: 1997-05 Impact factor: 5.191
Authors: C Merry; M G Barry; F Mulcahy; M Ryan; J Heavey; J F Tjia; S E Gibbons; A M Breckenridge; D J Back Journal: AIDS Date: 1997-03-15 Impact factor: 4.177
Authors: M Markowitz; M Saag; W G Powderly; A M Hurley; A Hsu; J M Valdes; D Henry; F Sattler; A La Marca; J M Leonard Journal: N Engl J Med Date: 1995-12-07 Impact factor: 91.245
Authors: S A Danner; A Carr; J M Leonard; L M Lehman; F Gudiol; J Gonzales; A Raventos; R Rubio; E Bouza; V Pintado Journal: N Engl J Med Date: 1995-12-07 Impact factor: 91.245
Authors: D J Kempf; K C Marsh; J F Denissen; E McDonald; S Vasavanonda; C A Flentge; B E Green; L Fino; C H Park; X P Kong Journal: Proc Natl Acad Sci U S A Date: 1995-03-28 Impact factor: 11.205
Authors: Monique M R de Maat; G Corine Ekhart; Alwin D R Huitema; Cornelis H W Koks; Jan W Mulder; Jos H Beijnen Journal: Clin Pharmacokinet Date: 2003 Impact factor: 6.447
Authors: Kimberly K Scarsi; Kristin M Darin; Catherine A Chappell; Stephanie M Nitz; Mohammed Lamorde Journal: Drug Saf Date: 2016-11 Impact factor: 5.606